AG
EGRX

Aperio Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Aperio Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$493K Buy
10,594
+2,822
+36% +$132K ﹤0.01% 1975
2020
Q3 		$330K Buy
7,772
+1,581
+26% +$69.2K ﹤0.01% 2030
2020
Q2 		$297K Buy
+6,191
New +$309K ﹤0.01% 2030
2019
Q3 		– Sell
-1,882
Closed -$105K – 2810
2019
Q2 		$105K Buy
+1,882
New +$98.2K ﹤0.01% 2375
2017
Q3 		– Sell
-3,579
Closed -$282K – 2243
2017
Q2 		$282K Buy
+3,579
New +$293K ﹤0.01% 1932

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Aperio Group's EGRX Position: Q4 2020 in Review

Aperio Group increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 36% in Q4 2020, buying an estimated $132K and bringing the position to 10,594 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #1975.

Aperio Group first reported a position in EGRX in Q2 2017 and has held it in 5 quarters since. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

  • Aperio Group held 10,594 shares of Eagle Pharmaceuticals, Inc. worth $493K as of Q4 2020.
  • Aperio Group bought 2,822 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $132K.
  • Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1975 holding.
  • Aperio Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and has held it in 5 quarters since.
  • 166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.